Home Cart Sign in  
Chemical Structure| 262438-43-7 Chemical Structure| 262438-43-7

Structure of ATN-161
CAS No.: 262438-43-7

Chemical Structure| 262438-43-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ATN-161 is a five-amino-acid peptide derived from the synergy region of fibronectin and a beta integrin antagonist with antitumor activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ATN-161

CAS No. :262438-43-7
Formula : C23H35N9O8S
M.W : 597.64
SMILES Code : O=C(N)C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CNC=N1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O
MDL No. :MFCD30478885
InChI Key :MMHDBUJXLOFTLC-WOYTXXSLSA-N
Pubchem ID :9960285

Safety of ATN-161

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ATN-161

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • Integrin

In Vitro:

Cell Line
Concentration Treated Time Description References
Human aortic endothelial cells (HAEC) 100 μg/mL 6 hours Evaluate VCAM-1 and ICAM-1 protein expression PMC4096780
Human aortic endothelial cells (HAEC) 100 μg/mL 6 hours Evaluate oxLDL-induced monocyte adhesion PMC4096780
VeroE6 cells 1 μM to 10 μM 1 hour To assess the ability of ATN-161 to inhibit SARS-CoV-2 infection. Results showed that ATN-161 increased cell viability at concentrations as low as 1 μM and reduced cytopathic effects at 10 μM. PMC7566794
DU145 prostate cancer cells 1 μg/ml 24 hours To evaluate the inhibitory effect of PHSCN peptide on the invasive ability of DU145 cells. Results showed that PHSCN peptide significantly reduced the invasive ability of DU145 cells, with a six-fold decrease compared to untreated cells. PMC1564117
Huh7 cells 10 μmol/ml 24 hours Inhibited OCT4 mRNA expression PMC9719217
HCCLM3 cells 10 μmol/ml 24 hours Inhibited NANOG and OCT4 mRNA expression, reduced YAP activation PMC9719217
Human aortic endothelial cells (HAECs) 50 μM 30 minutes To evaluate the effect of ATN-161 on shear stress-induced endothelial cell activation. Results showed that ATN-161 did not affect shear stress-induced activation of FAK, PAK2, and NF-κB. PMC4597278
HEK293T-ACE2 cells 0.1 mM 6 hours Investigate the effect of ATN-161 on rVSV-S infection, results showed that ATN-161 exhibited no inhibition effect on rVSV-S infection PMC10723138
Adult tenocytes 100 μM 60 minutes To study the effect of ATN-161 on Pro-Hyp uptake, results showed ATN-161 significantly inhibited Pro-Hyp uptake PMC8239475
BEnd.3 cells 5, 10, 25, and 50 µM 6h OGD/24h reoxygenation ATN-161 effectively inhibited OGD/R-induced integrin α5, NLRP3 inflammasome, oxidative stress, mitochondrial damage, fibrosis, and tight junction protein loss. PMC8380192
Human aortic endothelial cells (HAEC) 100 μg/mL indicated times Evaluate VCAM-1 and ICAM-1 mRNA expression PMC4096780

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CD4/H11001CD45RBhigh T-cell transfer colitis model Intraperitoneal injection 1 mg/kg Three times a week for six weeks ATN-161 significantly reduced histopathological scores and angiogenic index in CD4/H11001CD45RBhigh colitis, indicating its therapeutic effect by inhibiting angiogenesis during experimental colitis. PMC1762465
Mice IL10-deficient mice and DSS-induced colitis model Intraperitoneal injection 1 mg/kg Every other day for 6 weeks To evaluate the therapeutic effect of ATN-161 on experimental colitis. Results showed that ATN-161 significantly reduced the Disease Activity Index (DAI), histological colitis score, and mean vascular density (MVD), and decreased the production of inflammatory cytokines. PMC1954843
K18-hACE2 transgenic mice SARS-CoV-2 infection model Intravenous injection 1 mg/kg Single or repeated doses within 48 hours post-infection Reduced lung viral load, viral immunofluorescence, and improved lung histology PMC8352850
Mice Ischemic stroke model Intraperitoneal injection 1 mg/kg Immediately after reperfusion, on post-stroke day (PSD)1 and PSD2 To evaluate the therapeutic effects of ATN-161 on ischemic stroke, results showed ATN-161 significantly reduced infarct volume, edema, and functional deficits, while also reducing BBB permeability and inflammatory responses PMC7370357
BALB/c mice Colorectal cancer liver metastasis model Intraperitoneal injection 1 mg/kg Every two days ATN-161 inhibits tumor metastasis PMC10650826
Mice Stroke model Intraperitoneal injection 1 mg/kg Single dose To test whether combination treatment of ATN-161 with hNSC transplantation further benefits stroke outcome. Results showed that ATN-161 combined with hNSC transplantation reduced infarct size and attenuated the induction of proinflammatory factors and matrix metalloproteases. PMC8647207
ApoE knockout mice Atherosclerosis model Intraperitoneal injection 5 mg/kg Three times per week for 7 days To evaluate the effect of ATN-161 on atherosclerotic plaque formation. Results showed that ATN-161 did not affect plaque formation or inflammatory responses. PMC4597278
ApoE-deficient mice High-fat Western Diet-induced atherosclerosis model Intraperitoneal injection 5 mg/kg Three times a week for 8 weeks Evaluate the effect of ATN-161 on atherosclerotic plaque development PMC4096780
Athymic nude mice DU145 prostate cancer xenograft model Intravenous injection 50 mg/kg Three times per week, continued until the end of the experiment To evaluate the inhibitory effect of PHSCN peptide on DU145 tumor recurrence and metastasis. Results showed that PHSCN peptide significantly inhibited tumor recurrence and metastasis, with all treated mice remaining recurrence- and metastasis-free for 30 weeks post-surgery. PMC1564117

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00131651 Carcinoma, Renal Cell PHASE2 TERMINATED - University of California Irvin... More >>e, Chao Family Comprehensive Cancer Center, Irvine, California, 92868, United States|University of California San Francisco Comprehensive Cancer Center, San Francisco, California, 94115, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44165, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, 53792-6164, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.37mL

1.67mL

0.84mL

16.73mL

3.35mL

1.67mL

References

 

Historical Records

Categories